Newsletter Tool

Today’s Big News

Jun 26, 2025

Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions

Novartis pens ProFound pact, offering up $750M biobucks per cardiovascular target

Altimmune's stock sinks on mixed phase 2 MASH results for GLP-1 drug

Hummingbird uses VISTA buzz to secure $290M pact for phase 2-ready tumor drug

Alto misses primary efficacy endpoint in phase 2 depression trial

Invivyd claims Pemgarda mAB follow-up could hold its own against COVID vaccines

ACIP proposes new work group to probe childhood vaccine schedules following RFK Jr. upheaval

16 House Republicans tell leaders Senate's Medicaid changes go too far, threaten pulling support

Featured

Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions

By Angus Liu

Less than two months after Vor Bio telegraphed a strategic review, the former cell therapy biotech has made a surprise comeback with a potential $4 billion deal licensing a China-made autoimmune asset.

Novartis pens ProFound pact, offering up $750M biobucks per cardiovascular target

By Gabrielle Masson

Novartis is penning a four-year pact with ProFound Therapeutics to create new therapeutics for heart disease, with $750 million in biobucks up for grabs per target.

Altimmune's stock sinks on mixed phase 2 MASH results for GLP-1 drug

By James Waldron

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 metabolic dysfunction-associated steatohepatitis study, while still showcasing the asset’s weight loss potential.

Hummingbird uses VISTA buzz to secure $290M pact for phase 2-ready tumor drug

By James Waldron

Hummingbird Bioscience could one day feather its nest with up to $290 million if its decision to license a phase 2-ready cancer drug to Percheron Therapeutics pays off.

Alto misses primary efficacy endpoint in phase 2 depression trial

By Nick Paul Taylor

Alto Neuroscience’s phase 2 depression trial has missed its primary efficacy endpoint, as patients on the drug candidate fared no better on a measure of alertness and mood than their peers on placebo. Still, the biotech pointed to other outcomes to make the case for the molecule.

Invivyd claims Pemgarda mAB follow-up could hold its own against COVID vaccines

By James Waldron

Invivyd has touted its follow-up to the FDA-authorized monoclonal antibody Pemgarda as potentially offering better protection against COVID-19 than available vaccines.

ACIP proposes new work group to probe childhood vaccine schedules following RFK Jr. upheaval

By Fraiser Kansteiner

While the first meeting of Robert F. Kennedy Jr.’s reshuffled Advisory Committee on Immunization Practices didn’t yield any votes Wednesday, comments from the panel’s new chair made it clear that changes could be coming for U.S. vaccine policy, especially as it pertains to kids.

16 House Republicans tell leaders Senate's Medicaid changes go too far, threaten pulling support

By Dave Muoio

A cadre of House Republicans from a swath of rural and non-rural states warned the Senate Majority Leader and House Speaker they "cannot support" a final reconciliation bill that includes the steeper changes to provider taxes and state directed payments outlined in the Senate Finance Committee's proposal.

FDA moves to block Olympus endoscope imports over manufacturing issues

By Conor Hale

The FDA is shutting the door to imports of certain endoscope hardware manufactured by Olympus, saying that a production site in Japan has failed to meet quality requirements.

Fierce podcasts

Don’t miss an episode

AbbVie, ADCs and the future of cancer care

This week on "The Top Line," AbbVie’s Daejin Abidoye, M.D., joins us to discuss the future of antibody drug conjugates.

Hype and hope for AI in rural healthcare

Inside Fierce Medtech's Fierce 15

Resources

Executive Summary

Specialized Support to Accelerate Biotech Success

Biotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster.